Saratov JOURNAL of Medical and Scientific Research

Cardioembolic stroke: risk factors, forecast, secondary prevention

Year: 2017, volume 13 Issue: №1 Pages: 187-192
Heading: Neurology Article type: Original article
Authors: Khakhanova O.N., Skorokhodov А.Р., Kutashov V.A., Ulyanova O.V.
Organization: Voronezh Emergency City Hospital №1, Voronezh State Medical University n.a. N.N. Burdenko
Summary:

The goal of the study is to evaluate the effectiveness of warfarin and the new direct anticoagulants (xarelto and pradaxa) in the secondary prevention of re-occurrence of cardioembolic stroke (CES). Material and methods. Inclusion criteria of patients in the study: migrated CES, confirmed the presence of a pathology of heart; reception of indirect anticoagulant (warfarin) or direct inhibitors of factor Xa (xarelto, pradaxa) to prevent re-CES. Exclusion criteria from the study: patients with other subtypes of ischemic stroke (IS), hemorrhagic stroke (HS), patients receiving aspirin, diseased patients with CES. The severity of neurological deficit was assessed according to the NIHSS, Rivermead, Rankine and Barthel scales. Results. By the end of the second year of monitoring after suffering CES number of patients with full recovery a self-service increased by 3% and decreased by the same number of patients with moderate and severe dependence on assistance in everyday life. More efficient and faster neurological function was restored in patients taking warfarin is worse in the group of patients receiving pradaxa. However, a second stroke in the first year after suffering several CES were more frequent in the group of patients receiving pradaxa, and usually fatal. Conclusion. Change of medications in the group of patients receiving xarelto and warfarin, other anticoagulants have not led to the emergence of recurrent stroke.

Bibliography:
1. Suslina ZA, Piradov MA, eds. Stroke: Diagnosis, treatment, prevention. Moscow: MEDpress; 2008; 288 p.
2. Kuznetsov AN, Vinogradov Ol, Rybalko NV. Modern approaches to antithrombotic therapy in patients with cardioembolic stroke. Neurology, Neuropsychiatry Psychosomatics 2013; Special issue 2: 28-39
3. Kutashov VA, Ulyanova OV. The most important predictors of cardioembolic stroke, which determine the clinical picture and outcome of the disease. Journal of neurology, psychiatry and neurosurgery 2016; 6: 51-55
4. Fonyakin AV, Geraskina LA, Suslin ZA. Stratification causes of cardioembolic stroke. Neurological journal 2002; (2): 8-11
5. Kutashov VA, Sazonov El, Ulyanova OV. Modern therapy of cerebrovascular diseases in the Voronezh region. Young scientist 2016; 3: 113-118
6. Kabdrahmanova GB, Ermagambetova АР, Suleymanov SY, Sinalova AG, Sarkulova Zh. Rehabilitation of patients in the recovery period of cerebral stroke in Kazakhstan. Zurnal nevrologii i psikhiatrii imeni S. S. Korsakova 2015; 115 (9-2): 64-67
7. Ulyanova OV, Kutashov VA. To the question of cardiogenic risk factors for ischemic stroke in young adults. Cardiovascular therapy and prevention 2015; 1 (15): 62-63
8. Fonyakin AV, Geraskina LA, Suslin ZA. Comparative evaluation of ongoing and paroxysmal atrial fibrillation in the pathogenesis cardiocerebral embolism. Cardiology 2002; (7): 4-6
9. Geraskina LA. Cardioembolic stroke: the diversity of the causes and current approaches to prevention. Neurology neuropsychiatry, psychosomatics. 2013; (4): 60-65
10. Fonyakin AV, Geraskina LA, Suslin ZA. Cardiac pathology in various pathogenic subtypes of ischemic stroke. Clinical Medicine 2002; (1): 25-28.

AttachmentSize
2017_01-1_187-192.pdf258.11 KB

Your rating: None Average: 1 (1 vote)